Reverse Innovation In China: An Interview With HUYA CEO Mireille Gillings
This article was originally published in PharmAsia News
Executive Summary
Eight years ago, HUYA’s CEO Mireille Gillings began screening compounds developed in China to bring them to global markets. Nowadays, the company says it has a database with more than 12,000 compounds and 2,000 biomarkers from China.